Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00833417 · ClinicalTrials.gov registry record · Phase 2
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell Carcinoma
A Phase 2 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 2
- Development phase
- 104
- Enrollment target
NCT00833417 is a Phase 2 study that has completed, run by Genentech. The registered enrollment target is 104 participants.
The verdict
NCT00833417, a Phase 2 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 104 participants
- Enrollment target
Study Summary
This is a Phase II, single-arm, two-cohort multicenter clinical trial evaluating the efficacy and safety of vismodegib (GDC-0449) in patients with advanced basal cell carcinoma. All patients receive vismodegib until evidence of progression, intolerable toxicities most probably attributable to vismodegib, or withdrawal from the study.
Interventions
- DRUG Vismodegib 150 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2009-02-10 |
| Est. Completion | 2014-04-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00833417
The ClinicalTrials.gov registry entry for NCT00833417 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vismodegib 150 mg is the first listed.
NCT00833417 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00833417 about?
NCT00833417 is a clinical study titled "A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell Carcinoma". This is a Phase II, single-arm, two-cohort multicenter clinical trial evaluating the efficacy and safety of vismodegib (GDC-0449) in patients with advanced basal cell carcinoma. All patients receive vismodegib until evidence of progression, intolerable toxicities most probably attributable to vismod...
What is the current status of trial NCT00833417?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 104 participants. The study started on 2009-02-10. Estimated completion is 2014-04-09.
What interventions are being tested in trial NCT00833417?
The interventions under investigation include: Vismodegib 150 mg (DRUG).
Who is sponsoring clinical trial NCT00833417?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.